Carolina Montano1, Margaret A Taub2, Andrew Jaffe3, Eirikur Briem4, Jason I Feinberg4, Rakel Trygvadottir4, Adrian Idrizi4, Arni Runarsson4, Birna Berndsen4, Ruben C Gur5, Tyler M Moore5, Rodney T Perry6, Doug Fugman7, Sarven Sabunciyan8, Robert H Yolken8, Thomas M Hyde9, Joel E Kleinman9, Janet L Sobell10, Carlos N Pato10, Michele T Pato10, Rodney C Go6, Vishwajit Nimgaonkar11, Daniel R Weinberger9, David Braff12, Raquel E Gur5, Margaret Daniele Fallin13, Andrew P Feinberg14. 1. Medical Scientist Training Program and Predoctoral Training Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland2Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland5Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Neuropsychiatry Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 6. Department of Epidemiology, University of Alabama at Birmingham, Birmingham. 7. Rutgers University Cell and DNA Repository, Piscataway, New Jersey. 8. Stanley Division of Developmental Neurovirology, Johns Hopkins School of Medicine, Baltimore, Maryland. 9. Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland. 10. Department of Psychiatry and Behavioral Sciences, Keck School of Medicine of University of Southern California, Los Angeles. 11. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 12. Department of Psychiatry, University of California San Diego School of Medicine, La Jolla13VISN22, Mental Illness Research, Education, and Clinical Center, VA Veterans Affairs San Diego Healthcare System, San Diego, California. 13. Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland5Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 14. Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland5Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland14Departments of Medicine and Biomedical Engineering, Johns Hopkins U.
Abstract
IMPORTANCE: DNA methylation may play an important role in schizophrenia (SZ), either directly as a mechanism of pathogenesis or as a biomarker of risk. OBJECTIVE: To scan genome-wide DNA methylation data to identify differentially methylated CpGs between SZ cases and controls. DESIGN, SETTING, AND PARTICIPANTS: Epigenome-wide association study begun in 2008 using DNA methylation levels of 456 513 CpG loci measured on the Infinium HumanMethylation450 array (Illumina) in a consortium of case-control studies for initial discovery and in an independent replication set. Primary analyses used general linear regression, adjusting for age, sex, race/ethnicity, smoking, batch, and cell type heterogeneity. The discovery set contained 689 SZ cases and 645 controls (n = 1334), from 3 multisite consortia: the Consortium on the Genetics of Endophenotypes in Schizophrenia, the Project among African-Americans To Explore Risks for Schizophrenia, and the Multiplex Multigenerational Family Study of Schizophrenia. The replication set contained 247 SZ cases and 250 controls (n = 497) from the Genomic Psychiatry Cohort. MAIN OUTCOMES AND MEASURES: Identification of differentially methylated positions across the genome in SZ cases compared with controls. RESULTS: Of the 689 case participants in the discovery set, 477 (69%) were men and 258 (37%) were non-African American; of the 645 controls, 273 (42%) were men and 419 (65%) were non-African American. In our replication set, cases/controls were 76% male and 100% non-African American. We identified SZ-associated methylation differences at 923 CpGs in the discovery set (false discovery rate, <0.2). Of these, 625 showed changes in the same direction including 172 with P < .05 in the replication set. Some replicated differentially methylated positions are located in a top-ranked SZ region from genome-wide association study analyses. CONCLUSIONS AND RELEVANCE: This analysis identified 172 replicated new associations with SZ after careful correction for cell type heterogeneity and other potential confounders. The overlap with previous genome-wide association study data can provide potential insights into the functional relevance of genetic signals for SZ.
IMPORTANCE: DNA methylation may play an important role in schizophrenia (SZ), either directly as a mechanism of pathogenesis or as a biomarker of risk. OBJECTIVE: To scan genome-wide DNA methylation data to identify differentially methylated CpGs between SZ cases and controls. DESIGN, SETTING, AND PARTICIPANTS: Epigenome-wide association study begun in 2008 using DNA methylation levels of 456 513 CpG loci measured on the Infinium HumanMethylation450 array (Illumina) in a consortium of case-control studies for initial discovery and in an independent replication set. Primary analyses used general linear regression, adjusting for age, sex, race/ethnicity, smoking, batch, and cell type heterogeneity. The discovery set contained 689 SZ cases and 645 controls (n = 1334), from 3 multisite consortia: the Consortium on the Genetics of Endophenotypes in Schizophrenia, the Project among African-Americans To Explore Risks for Schizophrenia, and the Multiplex Multigenerational Family Study of Schizophrenia. The replication set contained 247 SZ cases and 250 controls (n = 497) from the Genomic Psychiatry Cohort. MAIN OUTCOMES AND MEASURES: Identification of differentially methylated positions across the genome in SZ cases compared with controls. RESULTS: Of the 689 case participants in the discovery set, 477 (69%) were men and 258 (37%) were non-African American; of the 645 controls, 273 (42%) were men and 419 (65%) were non-African American. In our replication set, cases/controls were 76% male and 100% non-African American. We identified SZ-associated methylation differences at 923 CpGs in the discovery set (false discovery rate, <0.2). Of these, 625 showed changes in the same direction including 172 with P < .05 in the replication set. Some replicated differentially methylated positions are located in a top-ranked SZ region from genome-wide association study analyses. CONCLUSIONS AND RELEVANCE: This analysis identified 172 replicated new associations with SZ after careful correction for cell type heterogeneity and other potential confounders. The overlap with previous genome-wide association study data can provide potential insights into the functional relevance of genetic signals for SZ.
Authors: Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao Journal: N Engl J Med Date: 2005-09-19 Impact factor: 91.245
Authors: Muktar H Aliyu; Monica E Calkins; Charlie L Swanson; Paul D Lyons; Robert M Savage; Roberta May; Howard Wiener; Stephen McLeod-Bryant; Bernie Devlin; Vishwajit L Nimgaonkar; J Daniel Ragland; Raquel E Gur; Ruben C Gur; L Dianne Bradford; Neil Edwards; Joseph Kwentus; Joseph P McEvoy; Alberto B Santos; Stephen McCleod-Bryant; Clifton Tennison; Rodney C P Go; Trina B Allen Journal: Schizophr Res Date: 2006-08-02 Impact factor: 4.939
Authors: Monica E Calkins; Dorcas J Dobie; Kristin S Cadenhead; Ann Olincy; Robert Freedman; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Gregory A Light; Jim Mintz; Keith H Nuechterlein; Allen D Radant; Nicholas J Schork; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff Journal: Schizophr Bull Date: 2006-10-11 Impact factor: 9.306
Authors: Arames Crameri; Elisa Biondi; Katrin Kuehnle; Dieter Lütjohann; Karin M Thelen; Simona Perga; Carlos G Dotti; Roger M Nitsch; Maria Dolores Ledesma; M Hasan Mohajeri Journal: EMBO J Date: 2006-01-12 Impact factor: 11.598
Authors: B Roig; C Virgos; N Franco; L Martorell; J Valero; J Costas; A Carracedo; A Labad; E Vilella Journal: Mol Psychiatry Date: 2007-04-17 Impact factor: 15.992
Authors: Robin F Chan; Andrey A Shabalin; Carolina Montano; Eilis Hannon; Christina M Hultman; Margaret D Fallin; Andrew P Feinberg; Jonathan Mill; Edwin J C G van den Oord; Karolina A Aberg Journal: Schizophr Bull Date: 2020-02-26 Impact factor: 9.306